Page 94 - 201810
P. 94

第 35 卷第 10 期                            精   细   化   工                                 Vol.35, No.10
             2018 年 10 月                             FINE CHEMICALS                                Oct.   2018


              医药与日化原料
                         星点设计-效应面法优化制备右旋布洛芬/


                                                酸改性蒙脱土



                                       1
                                                                2
                                                   1
                                                                                          1*
                                                                             1
                             李婷婷 ,赵乐乐 ,郑子良 ,孙艺丹 ,张淑秋
                  (1.  山西医科大学  药学院  山西  太原  030001;2.  山西医科大学  转化医学研究中心  山西  太原  030001)
                 摘要:以右旋布洛芬为原料,酸化蒙脱土为药物载体,制得右旋布洛芬/酸改性蒙脱土 S(+)-IBU/acid-MMT 干混
                 悬剂。通过星点设计-效应面法优化右旋布洛芬/酸改性蒙脱土干混悬剂的制备工艺。以蒙脱土的载药量为考察指
                 标,采用三因素五水平星点设计考察了盐酸浓度、酸化时间、酸化温度对干混悬剂制备工艺的影响,并对结果
                 进行了二元多项式线性回归方程拟合,经效应面法预测最佳处方;借助 XRD 和 SEM 技术对干混悬剂进行了结
                 构表征。结果表明,右旋布洛芬/酸改性蒙脱土干混悬剂最佳制备条件为:盐酸浓度 3.3 mol/L,酸化时间 5.2 h,
                 酸化温度 54 ℃,在该条件下,干混悬剂载药量可达 443.7 mg/g,较优化前(352.4 mg/g)提高了 25.9%。星点设
                 计-效应面法适用于右旋布洛芬/酸改性蒙脱土干混悬剂制备工艺优化,以该方法建立的数学模型具有良好的预测
                 性,所得干混悬剂具有更高的载药量。
                 关键词:星点设计;效应面法;右旋布洛芬;酸化蒙脱土;医药与日化原料
                 中图分类号:O611.4      文献标识码:A     文章编号:1003-5214 (2018) 10-1702-06


                Optimization of Preparation of S(+)-Ibuprofen/Acid-Montmorillonite Dry

                 Suspension by Central Composite Design-Response Surface Methodology

                                                                 2
                                                                              1
                                   1
                                                 1
                                                                                               1*
                         LI Ting-ting , ZHAO Le-le , ZHENG Zi-liang , SUN Yi-dan , ZHANG Shu-qiu
                 (1.  College of Pharmacy, Shanxi  Medical University, Taiyuan  030001,  Shanxi, China; 2.  Translational Medicine
                 Research Center, Shanxi Medical University, Taiyuan 030001, Shanxi, China)
                 Abstract: The acid-montmorillonite  (acid-MMT)  was used as the carrier  of S(+)-ibuprofen (IBU)  to
                 produce  S(+)-IBU/acid-MMT dry suspension. The preparation  process of  S(+)-IBU/acid-MMT dry
                 suspension was optimized by central composites design-response surface methodology. Using drug loading
                 as indexes, a three-factor and five-level central composite design was employed to investigate three factors
                 affecting  S(+)-IBU/acid-MMT dry suspension  preparation including  hydrochloric acid concentration,
                 acidification time and acidification temperature. The  results were  fitted by second-order  polynomial
                 equation, and the  optimal formulation  was  predicted by response  surface methodology. The  prepared
                 S(+)-IBU/acid-MMT dry suspension were  characterized by XRD and SEM. The  optimum preparation
                 conditions of  S(+)-IBU/acid-MMT dry  suspension  were  obtained as follows: hydrochloric acid
                 concentration 3.3 mol/L, acidification time 5.2 h and acidification temperature 54 ℃. The loading capacity
                 under this kind of optimization condition was 443.7 mg/g, which was 25.9% higher than 352.4 mg/g before
                 optimization. The central composite design-response surface methodology is suitable for the optimization of
                 preparation process of S(+)-IBU/acid-MMT dry suspension, and the mathematical model established by this
                 method has good predictability. Moreover, the obtained dry suspension has a higher loading capacity.
                 Key words: central composite design; response surface methodology; S(+)-ibuprofen; acid-montmorillonite;
                 drug and cosmetic materials


                 收稿日期:2017-05-15;  定用日期:2018-02-12; DOI: 10.13550/j.jxhg.20170407
                 基金项目:国家自然科学基金(81571747);山西省青年科技研究基金(201601D202105);山西医科大学校博士启动基金(03201529);
                 山西医科大学青年基金(02201618)
                 作者简介:李婷婷(1984—),女,讲师,博士,E-mail:lily8631@163.com。联系人:张淑秋(1962—),女,教授,博士生导师,
                 E-mail:shuqiu.zhang@126.com。
   89   90   91   92   93   94   95   96   97   98   99